Core Viewpoint - MoonLake Immunotherapeutics (MLTX) shows significant upside potential with a mean price target of $76.43, indicating a 106.6% increase from the current price of $36.99 [1] Price Targets and Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $13.12, suggesting variability among analysts [2] - The lowest estimate of $55 indicates a 48.7% increase, while the highest estimate predicts a surge of 181.2% to $104 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 1.7% over the past month, with two estimates going higher and no negative revisions [12] - MLTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - QuinStreet (QNST) closed at $15.88, with a 1.4% gain over the past four weeks, and a mean price target of $28.40 suggests a 78.8% upside potential [1] - The mean estimate includes five short-term price targets with a standard deviation of $5.90, indicating variability; the lowest estimate of $19 represents a 19.7% increase, while the highest target of $35 suggests a 120.4% surge [2] - Analysts show strong agreement on QNST's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 31.4% over the past month, with two estimates rising and one falling [12] - QNST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]

Group 1 - Pagaya Technologies Ltd. (PGY) closed at $14.96, with a 49.8% gain over the past four weeks, and a mean price target of $22.69 suggests a 51.7% upside potential [1] - The average price targets from analysts range from a low of $13.75 to a high of $36, with a standard deviation of $7.04, indicating variability in estimates [2] - Analysts show strong agreement on PGY's ability to report better earnings, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for PGY's current year earnings has increased by 2.8% over the last 30 days, with no negative revisions [12] - PGY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [13]

Group 1 - Xperi (XPER) has shown a significant price increase of 27.7% over the past four weeks, with a mean price target of $18.25 indicating an upside potential of 118.8% [1] - The average price target ranges from a low of $12 to a high of $30, with a standard deviation of $8.02, suggesting variability in analysts' estimates [2] - The consensus price target is not the sole metric for investment decisions, as analysts' ability to set accurate price targets has been questioned [3] Group 2 - Strong agreement among analysts regarding XPER's earnings prospects, indicated by positive earnings estimate revisions, supports the expectation of stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for XPER's current year earnings has increased by 46.2%, with no negative revisions [12] - XPER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Core Viewpoint - Sangoma Technologies Corporation (SANG) has shown a significant price increase of 29.2% over the past four weeks, with a mean price target of $8.36 indicating a potential upside of 40.5% from the current price of $5.95 [1] Price Targets and Analyst Consensus - The average price target consists of four estimates ranging from a low of $7.94 to a high of $9.50, with a standard deviation of $0.76, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates a potential increase of 33.5%, while the highest suggests a 59.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding SANG's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 8.3%, with two estimates moving higher and no negative revisions [12] - SANG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Group 1 - Trevi Therapeutics, Inc. (TRVI) shares have increased by 4.1% over the past four weeks, closing at $6.46, with a mean price target of $19.06 indicating a potential upside of 195.1% [1] - The average of eight short-term price targets ranges from a low of $11 to a high of $29, with a standard deviation of $6.01, suggesting a potential increase of 70.3% to 348.9% from the current price level [2] - Analysts show strong agreement regarding TRVI's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for TRVI's current year has increased by 21.5% over the past month, with five estimates rising and no negative revisions [12] - TRVI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [10][13]

Core Viewpoint - Crexendo (CXDO) has shown a significant price increase of 24.2% over the past four weeks, with analysts suggesting further upside potential based on a mean price target of $8.30, indicating a 42.9% increase from the current price of $5.81 [1] Price Targets and Analyst Estimates - The mean price target consists of five short-term estimates with a standard deviation of $0.97, where the lowest estimate is $7.50 (29.1% increase) and the highest is $10 (72.1% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about CXDO's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, two earnings estimates have been revised upward, leading to an 18.2% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - CXDO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]

uniQure (QURE) closed the last trading session at $12.81, gaining 32.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.50 indicates a 161.5% upside potential.The average comprises 10 short-term price targets ranging from a low of $20 to a high of $70, with a standard deviation of $15.33. While the lowest estimate indicates an increase of 56.1% from the current price level, the ...

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 8.2% recently, with a mean price target of $31.22 suggesting a potential upside of 30.7% from the current price of $23.89 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1.48, indicating variability among analysts [2] - The lowest price target is $30, representing a 25.6% increase, while the highest target is $34, indicating a potential surge of 42.3% [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about BLFS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 19.2% over the past month, with no negative revisions [12] - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of AudioEye (AEYE) have gained 14.3% over the past four weeks to close the last trading session at $12.90, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.40 indicates a potential upside of 73.6%.The mean estimate comprises five short-term price targets with a standard deviation of $2.51. While the lowest estimate of $20 indicates a 55% increase from the current price ...